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Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell
transplantation (allo-HSCT) currently remain among the major causes of treatment
failure in malignant and non-malignant hematological diseases. A second allo-HSCT is
a valuable therapeutic option to salvage those situations. During the 8th annual
harmonization workshops of the french Society of bone marrow transplantation and
cellular therapy (SFGM-TC), a designated working group reviewed the literature in
order to elaborate unified guidelines on feasibility, indications, donor choice and
conditioning in the case of a second allo-HSCT. In case of relapse, a second allo-HSCT
with reduced intensity or non-myeloablative conditioning is a reasonable option,
particularly in patients with a good performance status (Karnofsky/Lansky>80%), low
co-morbidity score (EBMT score≤3), a longer remission duration after the first allo-
HSCT (>6 months), and who present low disease burden at the time of second allo-
HSCT. Matched related donors tend to be associated with better outcomes. In the
presence of graft dysfunction (primary and secondary graft rejection), an
immunoablative conditioning regimen is recommended. A donor change remains a











Second allogeneic hematopoietic stem cell transplant: Guidelines from the
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